ChiCTR2600125114 版本V1.0 版本创建时间2026/05/21 14:47:23 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2600125114 

最近更新日期:

Date of Last Refreshed on:

2026-05-21 14:47:18 

注册时间:

Date of Registration:

2026-05-21 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

艾司氯胺酮对老年股骨骨折患者术后谵妄的影响:一项随机双盲安慰剂对照研究

Public title:

Effect of Esketamine on Postoperative Delirium in Elderly Patients with Femoral Fracture: A Randomized, Double-Blind, Placebo-Controlled Study

注册题目简写:

English Acronym:

研究课题的正式科学名称:

艾司氯胺酮对老年股骨骨折患者术后谵妄的影响:一项随机双盲安慰剂对照研究

Scientific title:

Effect of Esketamine on Postoperative Delirium in Elderly Patients with Femoral Fracture: A Randomized, Double-Blind, Placebo-Controlled Study

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

邱建豪 

研究负责人:

刘爱杰 

Applicant:

Jianhao Qiu 

Study leader:

Aijie Liu 

申请注册联系人电话:

Applicant telephone:

+86 178 6128 1136

研究负责人电话:

Study leader's
telephone:

+86 186 6180 1683

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

kyrie2cavs@163.com

研究负责人电子邮件:

Study leader's E-mail:

clara_2074@qdu.edu.cn

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

山东省青岛市崂山区海尔路 59 号

研究负责人通讯地址:

山东省青岛市崂山区海尔路 59 号

Applicant address:

59 Haier Road, Laoshan District, Qingdao, Shandong, China

Study leader's address:

59 Haier Road, Laoshan District, Qingdao, Shandong, China

申请注册联系人邮政编码:

Applicant postcode:

266100

研究负责人邮政编码:

Study leader's postcode:

266100

申请人所在单位:

青岛大学附属医院

Applicant's institution:

The Affiliated Hospital of Qingdao University

研究负责人所在单位:

青岛大学附属医院

Affiliation of the Leader:

The Affiliated Hospital of Qingdao University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

[临研]伦审QYFYEC2025-106

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

青岛大学附属医院医学伦理委员会

Name of the ethic committee:

Medical Ethics Committee of the Affiliated Hospital of Qingdao University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-07-09 00:00:00

伦理委员会联系人:

朱婕

Contact Name of the ethic committee:

Jie Zhu

伦理委员会联系地址:

山东省青岛市崂山区海尔路 59 号

Contact Address of the ethic committee:

59 Haier Road, Laoshan District, Qingdao, Shandong, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 532 8291 1869

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

青岛大学附属医院

Primary sponsor:

The Affiliated Hospital of Qingdao University

研究实施负责(组长)单位地址:

山东省青岛市崂山区海尔路 59 号

Primary sponsor's address:

59 Haier Road, Laoshan District, Qingdao, Shandong, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

山东省

市(区县):

Country:

China

Province:

ShanDong Province

City:

单位(医院):

青岛大学附属医院

具体地址:

山东省青岛市崂山区海尔路 59 号

Institution
hospital:

The Affiliated Hospital of Qingdao University

Address:

59 Haier Road, Laoshan District, Qingdao, Shandong, China

经费或物资来源:

自筹

Source(s) of funding:

Self-raised

研究疾病:

谵妄  

Target disease:

Delirium

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

本试验的目的是评估在行股骨骨折手术的老年患者群体中,给予小剂量的艾司氯胺酮进行镇痛镇静,对于术后发生的谵妄是否具有治疗或者预防效果。  

Objectives of Study:

The aim of this trial was to evaluate whether low-dose esketamine administered for analgesia and sedation has a preventive or therapeutic effect on postoperative delirium in elderly patients undergoing femoral fracture surgery.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

1. 年龄>=65岁; 2. 美国麻醉学会(ASA)分级I-III; 3. MMSE评分大于26; 4. 无既往精神病史,谵妄史; 5. 知情研究内容并签署研究同意书。

Inclusion criteria

1. Aged >= 65 years; 2. American Society of Anesthesiologists (ASA) physical status classification Class I–III; 3. Mini-Mental State Examination (MMSE) score > 26; 4. No previous history of psychiatric disease or delirium; 5. Fully informed of the study contents and signed the informed consent form.

排除标准:

1. 既往有颅脑肿瘤、脑出血、大面积脑梗塞等神经系统疾病,或抑郁症、痴呆等精神病史; 2. 术后出现严重焦虑抑郁情绪或合并肺部感染、肺栓塞、脑梗等严重并发症; 3. 正在参与其他实验或拒绝实验; 4. MMSE小于等于26分者; 5. 艾司氯胺酮等麻醉药物过敏者。

Exclusion criteria:

1. Previous history of neurological diseases such as intracranial tumor, cerebral hemorrhage and large-area cerebral infarction, or psychiatric history including depression and dementia; 2. Patients with severe anxiety and depression after surgery, or complicated with severe complications such as pulmonary infection, pulmonary embolism and cerebral infarction; 3. Participation in other ongoing clinical trials or refusal to participate in this study; 4. Mini-Mental State Examination (MMSE) score <= 26 points; 5. Allergy to esketamine or other anesthetic drugs.

研究实施时间:

Study execute time:

From 2026-05-16 00:00:00 To 2027-05-16 00:00:00  

征募观察对象时间:

Recruiting time:

From 2026-06-01 00:00:00 To 2027-05-01 00:00:00

干预措施:

Interventions:

组别:

对照组

样本量:

78

Group:

Control group

Sample size:

干预措施:

在麻醉诱导中使用安慰剂

干预措施代码:

Intervention:

Placebo was used during anesthesia induction

Intervention code:

组别:

艾司氯胺酮组

样本量:

78

Group:

Esketamine Group

Sample size:

干预措施:

在麻醉诱导中使用艾司氯胺酮(0.2mg/kg)

干预措施代码:

Intervention:

Esketamine was used during anesthesia induction(0.2mg/kg)

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

山东省 

市(区县):

 

Country:

China

Province:

ShanDong Province

City:

单位(医院):

青岛大学附属医院 

单位级别:

三甲 

Institution
hospital:

The Affiliated Hospital of Qingdao University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

术后谵妄发生率

指标类型:

主要指标

Outcome:

Incidence of postoperative delirium

Type:

Primary indicator

测量时间点:

术后起一至七天

测量方法:

Measure time point of outcome:

1–7 days after surgery

Measure method:

指标中文名:

拔管时间

指标类型:

次要指标

Outcome:

Extubation time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

恢复室停留时间

指标类型:

次要指标

Outcome:

PACU stay time

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

血糖

指标类型:

次要指标

Outcome:

Blood glucose

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

乳酸

指标类型:

次要指标

Outcome:

Lactate

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

C反应蛋白

指标类型:

次要指标

Outcome:

C-reactive protein

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白介素6

指标类型:

次要指标

Outcome:

Interleukin-6

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

白细胞计数

指标类型:

次要指标

Outcome:

WBC count

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中性粒细胞计数

指标类型:

次要指标

Outcome:

Neutrophil count

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

中性粒细胞占比

指标类型:

次要指标

Outcome:

Neutrophil percentage

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 65 years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

我们采用计算机生成随机数字序列进行随机分组,按照1:1比例将受试者分配至对照组(Control group,C Group)艾司氯胺酮组(Esketamine group,E Group),随机序列由不参与患者管理、麻醉实施、术后随访及统计分析的独立研究人员生成。

Randomization Procedure (please state who generates the random number sequence and by what method):

Randomization was performed using a computer-generated random number sequence. Participants were allocated at a 1:1 ratio to either the control group (C group) or the esketamine group (E group). The random sequence was generated by an independent researcher who was not involved in patient management, anesthesia administration, postoperative follow-up, or statistical analysis.

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

双盲(整个过程中,受试者、麻醉实施者、围术期随访评估者及统计分析人员均对分组情况保持盲态)

Blinding:

Double-blind(Throughout the entire study period, subjects, anesthesiologists, perioperative follow-up evaluators, and statistical analysts remained blinded to group allocation.)

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

否No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

不共享

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Not shared

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据保存在病历记录表中并在电脑中备份

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

All study data are stored in medical record forms and backed up on computers.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-05-21 14:47:18